Neurocrine Biosciences Aktie: Vertrauen der Investoren gewinnen!
Die Neurocrine Biosciences Aktie verzeichnete am 9. November 2024 einen bemerkenswerten Kursanstieg von 1,42% und schloss bei 125,74 USD. Dieser…
118,300€
5,96%
Echtzeit-Aktienkurs Neurocrine Biosciences
Bid:
Ask:
Nachrichten zur Neurocrine Biosciences Aktie
Neurocrine Biosciences Aktie: Gute Aussichten!
Neurocrine Biosciences (NASDAQ: NBIX) verzeichnete im dritten Quartal 2024 eine beeindruckende Leistung. Das Biopharma-Unternehmen meldete einen robusten Umsatzanstieg, der hauptsächlich…
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript
…
Neurocrine Biosciences, Inc. 2024 Q3 - Results - Earnings Call Presentation
…
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.…
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) –…
Neurocrine Biosciences: Starke Quartalszahlen treiben die Aktie in Richtung Rekordhoch bei 150,39 USD - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Neurocrine Biosciences-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Neurocrine Biosciences Inc.…
Neurocrine Biosciences CHRO Julie Cooke sells $1.4m in stock By Investing.com
Neurocrine Biosciences CHRO Julie Cooke sells $1.4m in stock…
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its…
Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript
…
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further…
Neurocrine Biosciences executive sells $725k in stock By Investing.com
Neurocrine Biosciences executive sells $725k in stock…
Neurocrine Biosciences exec sells over $10m in company stock By Investing.com
Neurocrine Biosciences exec sells over $10m in company stock…
Neurocrine Biosciences exec sells shares worth over $420k By Investing.com
Neurocrine Biosciences exec sells shares worth over $420k…
Neurocrine Biosciences Q4 2023 Earnings Preview
…
Pro Research: Wall Street peers into Neurocrine Biosciences prospects By Investing.com
Pro Research: Wall Street peers into Neurocrine Biosciences prospects…
Wall Street dives into Neurocrine Biosciences By Investing.com
© Reuters Explore Wall Street’s expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon.…
BUSINESS WIRE: Biocytogen schließt Multi-Target-Vereinbarung in Bezug auf Antikörper mit Neurocrine Biosciences ab
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.PEKING UND SAN DIEGO --(BUSINESS WIRE)-- 20.12.2023…
Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies
Tokyo, Japan and Cambridge, UK, 6 December 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), notes its partner Neurocrine…
Pro Research: Wall Street dives into Neurocrine Biosciences By Investing.com
Pro Research: Wall Street dives into Neurocrine Biosciences…
Pro Research: Wall Street digs into Neurocrine Biosciences prospects By Investing.com
Pro Research: Wall Street digs into Neurocrine Biosciences prospects…
Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript
…
Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Schizophrenia Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Otsuka, Boehringer Ingelheim, Merck, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Lyndra, Cerevel
The schizophrenia market is expected to grow significantly owing to an increase in the patient pool due to changes in…
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
Tokyo, Japan and Cambridge, UK, 12 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), has been notified by…
Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatment
Neurocrine Biosciences Inc. NBIX said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of…
Neurocrine nabs FDA label expansion for Ingrezza
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Neurocrine announces FDA approval of INGREZZA capsules
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Neurocrine Biosciences Ingrezza Gets FDA Approval
Neurocrine Biosciences' Ingrezza Gets FDA Approval...…
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended…
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of 23.38% and 0.98%, respectively, for the quarter ended June 2023. Do the…
Neurocrine Biosciences Inc Q2 Earnings Summary
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Neurocrine Biosciences Inc (NBIX):Earnings: $95.5 million in Q2 vs. -$16.9 million…
Form 10-Q NEUROCRINE BIOSCIENCES For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $440 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2023 Net Product Sales…
Form 8-K NEUROCRINE BIOSCIENCES For: Aug 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Neurocrine Biosciences Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K NEUROCRINE BIOSCIENCES For: Jul 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors
SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it appointed Christine A. Poon,…
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, August 1 SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:…
BMO upgrades Neurocrine to market perform on Ingrezza outlook
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Expert Ratings for Neurocrine Biosciences
Latest Ratings for NBIX
DateFirmActionFromTo Mar 2022Piper SandlerDowngradesOverweightNeutral Feb 2022Goldman SachsUpgradesNeutralBuy Feb 2022Morgan StanleyMaintainsEqual-Weight
View…
Form 8-K NEUROCRINE BIOSCIENCES For: May 17
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Neurocrine sees August FDA action date for valbenazine for chorea
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Neurocrine upgraded to buy at Guggenheim on Ingrezza growth, pipeline
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Aufsichtsrat verkauft Aktien von Neurocrine Biosciences im Wert von 436.135$
Rastetter, William H. - Aufsichtsrat - Tag der Transaktion: 2023-05-01...…
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the…
Neurocrine Biosciences Non-GAAP EPS of -$0.51, revenue of $420.4M beats by $11.33M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
INGREZZA® (valbenazine) First Quarter Net Product Sales of $410 Million INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Reiterated at $1.67…
Form 8-K NEUROCRINE BIOSCIENCES For: May 03
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…